BROSSARD, Quebec, April 02, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:
ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE
platform based on Artificial Intelligence (AI), announces today the opening of the first eye screening
diabetic clinic with a world leading global health research institute in Dhaka, Bangladesh.
Eyes For All (“EFA”) is working with a group that is operating multiple clinics and hospitals in the country.
They have multiple diabetes clinics and, with the help of EFA, want to screen patients for diabetic retinopathy (“DR”) when
patients come to evaluate their blood sugar. The plan is to screen up to 80 patients per day at the initial clinic. In the coming
months, they expect to expand the coverage in other diabetic clinics.
The International Diabetes Federation (“IDF”) estimates that by 2030, Bangladesh would emerge as one of the countries with the largest number
of people with type 2 diabetes. Diabetes in Bangladesh is growing at an alarming rate. Nearly half of the population with diabetes,
51.2%, don’t know that they have diabetes and don’t receive any treatment. A greater number of the diabetes population comes from
educated and affluent families with 40.7% coming from the richest quintile.
EFA is a health technology consultancy company with relationships in Bangladesh across Non-Government
Organizations (“NGOs”), healthcare research institutes and the public sector hospital network. “We are delighted to be able to
partner with Diagnos in the effort to conduct DR screening across Bangladesh. The mismatch between existing healthcare
infrastructure and demand in the country means that Diagnos’s proprietary technology will make a tremendous difference to the lives
of many people in the country”, said Mr. Zahed Chowdhury, cofounder of Eyes For All.
“We are welcoming our partner first customer and we are looking forward to continuing our work with EFA to fight
to prevent vision loss in Bangladesh and Asia. This new customer is a strong example of the incremental value of an indirect model
to execute our growth plan in the country with large culture differential”, said Yves-Stéphane Couture, Diagnos vice-president of
sales.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of
its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that
integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image
enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the
internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for
commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking
compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
This news release contains forward-looking information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as
a result of new information, future events or otherwise. The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
